Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review

• Published in: Frontiers in pharmacology 2023-12, Vol.14, p.1255785
• Main Authors: Lin, Jietao, Chen, Wenmin, Zhong, Sha, Qian, Kai, Chen, Hanrui, Lin, Lizhu
• Format: Article
• Language: English
• Subjects: anlotinib; case report; cervical carcinoma; Pharmacology; posterior reversible encephalopathy syndrome; targeted therapy
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1255785

Posterior reversible encephalopathy syndrome (PRES), a neurological disorder with an unknown aetiology, is characterised by visual impairment, headache, vomiting, seizures, and transient alterations in consciousness. We present the case of a 49-year-old woman with advanced cervical carcinoma who received second-line therapy with oral anlotinib (12 mg, days 1-14, every 21 days) and injectable tislelizumab (200 mg, day 1, every 21 days). After 7 days of anlotinib administration, she began experiencing symptoms suggestive of PRES and was diagnosed on day 11. Interruption of anlotinib and supportive treatment led to recovery of her binocular vision. The Naranjo score (+5) graded the causality of this reaction as probable, suggesting the possibility that the event may have been an adverse reaction to anlotinib. This case report was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Reference no. K-2023-068, 2023/06/09). Informed consent was obtained from the patient and her family.